/ACOG
ACOG Stock - Alpha Cognition Inc. Common Stock
Financial Services|Financial - ConglomeratesNASDAQ
$5.56+10.10%
+$0.51 (+10.10%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.15
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+223.7%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACOG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.50 – $5.62
TARGET (TP)$18.00
STOP LOSS$5.12
RISK/REWARD1:28.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.62
52W High$11.54
52W Low$3.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-11,860,655 | $-9,617,814 | $-13,465,624 | $-11,568,728 | $-5,705,180 |
| Net Income | $-14,636,865 | $-13,772,567 | $-12,114,698 | $-19,545,016 | $-5,784,207 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.02 | $-3.84 | $-4.50 | $-9.25 | $-2.79 |
Company Overview
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 259.7% Upside
Now
$20
Low
$20
Average
$20
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 18th 2025 | H.C. Wainwright | Initiation | Buy | $20 |
Earnings History & Surprises
ACOGBeat Rate
67%
Last 6 quarters
Avg Surprise
+30.3%
EPS vs Estimate
Beats / Misses
4/2
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
+64.8%
$-0.35vs$-1.00
Q4 24
+69.0%
$-0.31vs$-1.00
Q1 25
-6.3%
$-0.51vs$-0.48
Q2 25
+65.5%
$-0.20vs$-0.58
Q3 25
-41.3%
$-0.65vs$-0.46
Q4 25
+30.2%
$-0.30vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.26 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.43 | $-0.30 | +30.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.46 | $-0.65 | -41.3% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.58 | $-0.20 | +65.5% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.48 | $-0.51 | -6.3% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-1.00 | $-0.31 | +69.0% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-1.00 | $-0.35 | +64.8% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | — | $-0.87 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-1.55 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.84 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.74 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.60 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.25 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.76 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.10 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.08 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-2.29 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-2.07 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.06 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-6.89 | — | — |
Latest News
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target
📈 PositiveBenzinga•Dec 19, 2025, 12:59 PM
Alpha Cognition Q3 Sales $2.300M Beat $2.033M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:04 PM
HC Wainwright & Co. Maintains Buy on Alpha Cognition, Lowers Price Target to $18
📈 PositiveBenzinga•Oct 20, 2025, 12:24 PM
Alpha Cognition To Present New Clinical Insights On Cholinesterase Inhibitors And ZUNVEYL At The American Society Of Consultant Pharmacists Annual Meeting On October 23–25, 2025, And The Neuroscience Education Institute Annual Congress On November 6–9, 2025
📈 PositiveBenzinga•Oct 14, 2025, 08:33 PM
Alpha Cognition To Present New Clinical Data On Cholinesterase Inhibitors And Its Investigational Therapy Zunveyl At American Society Of Consultant Pharmacists Annual Meeting, October 23–25, 2025.
📈 PositiveBenzinga•Oct 6, 2025, 12:34 PM
Alpha Cognition shares are trading higher. The company announced the pricing of its $35 million oversubscribed underwritten public offering of 5,600,000 common shares at a public offering price of $6.25 per share.
📈 PositiveBenzinga•Oct 1, 2025, 04:58 PM
Reported Earlier, Alpha Cognition Prices $35M Oversubscribed Public Offering Of 5,600,000 Shares At $6.25 Each To Accelerate ZUNVEYL Commercialization
📈 PositiveBenzinga•Oct 1, 2025, 05:49 AM
Alpha Cognition announces proposed public offering of common shares
➖ NeutralSeeking Alpha•Sep 30, 2025, 09:04 PM
Alpha Cognition Reveals Proposed Public Offering of Common Shares; No Size Disclosed
📉 NegativeBenzinga•Sep 30, 2025, 08:59 PM
Alpha Cognition Files For Mixed Shelf Of Up To $250M
➖ NeutralBenzinga•Aug 22, 2025, 08:04 PM
Frequently Asked Questions about ACOG
What is ACOG's current stock price?
Alpha Cognition Inc. Common Stock (ACOG) is currently trading at $5.56 per share. The stock has moved +10.10% today.
What is the analyst price target for ACOG?
The average analyst price target for ACOG is $18.00, based on 1 analyst.
What sector is Alpha Cognition Inc. Common Stock in?
Alpha Cognition Inc. Common Stock operates in the Financial Services sector, specifically within the Financial - Conglomerates industry. The company is traded on the NASDAQ exchange.
What is ACOG's market cap?
Alpha Cognition Inc. Common Stock has a market capitalization of $0.08 billion, making it a small-cap company.
Does ACOG pay dividends?
No, Alpha Cognition Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Financial Services SectorCAPN
Cayson Acquisition Corp Ordinary shares
$10.62
Mkt Cap: $0.1B
CHPG
ChampionsGate Acquisition Corporation Class A Ordinary Share
$10.14
Mkt Cap: $0.1B
DTSQ
DT Cloud Star Acquisition Corporation
$10.75
Mkt Cap: $0.1B
FGBI
First Guaranty Bancshares, Inc.
$5.06
Mkt Cap: $0.1B
MAAS
Highest Performances Holdings Inc. American Depository Shares
$4.97
Mkt Cap: $1.6B
NOEM
CO2 Energy Transition Corp. Common Stock
$10.41
Mkt Cap: $0.1B
PROP
Prairie Operating Co.
$1.68
Mkt Cap: $0.1B
SRL
Scully Royalty Ltd.
$7.13
Mkt Cap: $0.1B
XYF
X Financial
$6.40
Mkt Cap: $0.0B
YHNA
YHN Acquisition I Limited
$10.71
Mkt Cap: $0.1B
Explore stocks similar to ACOG for comparison